Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Okuno

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 19, 2005
Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institutionKarin F Giordano, Aminah Jatoi, Alex A Adjei, et al.
Journal of Surgical Oncology|October 23, 2008
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665Burton L Eisenberg, Jonathan Harris, Charles D Blanke, et al.
Biomedical Physics & Engineering Express|February 29, 2020
Soft Tissue Sarcoma Stiffness and Perfusion Evaluation by MRE and DCE-MRI for Radiation Therapy Response Assessment: A Technical Feasibility StudyKay Pepin, Roger Grimm, Soudabeh Kargar, et al.
Annals of Surgical Oncology|December 29, 2011
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132Dian Wang, Qiang Zhang, Charles D Blanke, et al.
Annals of Surgical Oncology|July 14, 2026
Improved Oncologic Outcomes with Trimodality Therapy for Radiation-Associated Angiosarcoma of the BreastSaskia J Leonard, Tanya Hoskin, Brittany L Siontis, et al.
British Journal of Cancer|May 29, 2021
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomasBrian Schulte, Nisha Mohindra, Mohammed Milhem, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2021
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcomaMark Agulnik, Brian Schulte, Steven Robinson, et al.
Cancers|July 16, 2020
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue SarcomasVarun Monga, Keith M Skubitz, Seth Maliske, et al.
Journal of Clinical Medicine|April 13, 2023
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to SarcomaNatalie K Heater, Scott Okuno, Steven Robinson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2020
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapyAngela C Hirbe, Vanessa Eulo, Chang I Moon, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Lung Cancer (Amsterdam, Netherlands)|July 19, 2005
Ramifications of severe organ dysfunction in newly diagnosed patients with small cell lung cancer: contemporary experience from a single institutionKarin F Giordano, Aminah Jatoi, Alex A Adjei, et al.
Journal of Surgical Oncology|October 23, 2008
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665Burton L Eisenberg, Jonathan Harris, Charles D Blanke, et al.
Biomedical Physics & Engineering Express|February 29, 2020
Soft Tissue Sarcoma Stiffness and Perfusion Evaluation by MRE and DCE-MRI for Radiation Therapy Response Assessment: A Technical Feasibility StudyKay Pepin, Roger Grimm, Soudabeh Kargar, et al.
Annals of Surgical Oncology|December 29, 2011
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132Dian Wang, Qiang Zhang, Charles D Blanke, et al.
Annals of Surgical Oncology|July 14, 2026
Improved Oncologic Outcomes with Trimodality Therapy for Radiation-Associated Angiosarcoma of the BreastSaskia J Leonard, Tanya Hoskin, Brittany L Siontis, et al.
British Journal of Cancer|May 29, 2021
Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomasBrian Schulte, Nisha Mohindra, Mohammed Milhem, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2021
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcomaMark Agulnik, Brian Schulte, Steven Robinson, et al.
Cancers|July 16, 2020
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue SarcomasVarun Monga, Keith M Skubitz, Seth Maliske, et al.
Journal of Clinical Medicine|April 13, 2023
The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to SarcomaNatalie K Heater, Scott Okuno, Steven Robinson, et al.
European Journal of Cancer (Oxford, England : 1990)|July 27, 2020
A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapyAngela C Hirbe, Vanessa Eulo, Chang I Moon, et al.
Pageof 4